First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

被引：23
|
作者：
Baselga, J.
Bradbury, I.
Eidtmann, H.
Di Cosimo, S.
Aura, C.
De Azambuja, E.
Gomez, H.
Dinh, P.
Fauria, K.
Van Dooren, V.
Paoletti, P.
Goldhirsch, A.
Chang, T-W
Lang, I.
Untch, M.
Gelber, R. D.
Piccart-Gebhart, M.
机构：
[1] Vall dHebron Univ Hosp, NeoALTTO Study Team, Barcelona, Spain
[2] FSS Ltd, Kincraig, Scotland
[3] Univ Hosp Kiel, Kiel, Germany
[4] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain
[5] SOLTI Spanish Breast Canc Res Grp, Barcelona, Spain
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] Breast European Adjuvant Study Team, Brussels, Belgium
[8] Inst Nacl Enfermedades Neoplas, Lima, Peru
[9] Breast Int Grp, Brussels, Belgium
[10] GlaxoSmithKline, Collegeville, PA USA
[11] European Inst Oncol, Milan, Italy
[12] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[13] Natl Inst Oncol, Budapest, Hungary
[14] Charite, Acad Hosp, D-13353 Berlin, Germany
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-S3-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-3
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer
    Park, I. H.
    Lee, K. S.
    Kang, H. S.
    Kwon, Y.
    Kim, S. W.
    Lee, S.
    Jung, S. Y.
    Shin, K. H.
    Ko, K.
    Nam, B.
    Ro, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.
    Chen, Xiaosong
    Huang, Jiahui
    Tong, Yiwei
    Ren, Weili
    Yu, Jing
    Gao, Weiqi
    Zhu, Siji
    Hong, Jin
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [24] Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Hoadley, Katherine A.
    Barry, William T.
    Pitcher, Brandelyn N.
    Parker, Joel S.
    Wilkerson, Matthew D.
    Irvin, William, Jr.
    Henry, Norah Lynn
    Tolaney, Sara M.
    Dang, Chau
    Krop, Ian E.
    Berry, Donald A.
    Mardis, Elaine R.
    Perou, Charles M.
    Winer, Eric P.
    Hudis, Clifford A.
    Carey, Lisa A.
    CANCER RESEARCH, 2015, 75
  • [25] Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy
    Blackwell, K. L.
    Burstein, H. J.
    Sledge, G. W.
    Stein, S.
    Ellis, C.
    Casey, M.
    Baselga, J.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2009, 69 (24) : 499S - 499S
  • [26] Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)
    Fernandez, M.
    Calvo, I.
    Martinez, N.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia-Aranda, M.
    Suarez, A.
    -Rios, F. Lopez
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2012, 72
  • [27] Neoadjuvant pyrotinib versus pertuzumab in combination with trastuzumab and nab-Paclitaxel for patients with HER2-positive early or locally advanced breast cancer (Pyramid): A randomized, multicenter, open-label, phase 2 trial
    Zhang, Jin
    Liu, Qiang
    Jiang, Hongchuan
    Zhang, Jianguo
    Ou, Jianghua
    Chen, Dedian
    Tian, Fuguo
    Li, Yongqing
    Cheng, Xiaoming
    Ouyang, Zhong
    CANCER RESEARCH, 2022, 82 (04)
  • [28] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
    Fernandez Abad, Maria
    Calvo, Isabel
    Martinez, Noelia
    Herrero, Mercedes
    Quijano, Yolanda
    Duran, Hipolito
    Garcia Aranda, Mariola
    Suarez, Ana
    Lopez-Rios, Fernando
    Perez, Diego
    Perea, Sofia
    Hidalgo, Manuel
    Garca-Estevez, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
    Xu, B.
    Yan, M.
    Ma, F.
    Li, W.
    Ouyang, Q.
    Tong, Z.
    Teng, Y.
    Wang, S.
    Wang, Y.
    Geng, C.
    Luo, T.
    Zhong, J.
    Zhang, Q.
    Liu, Q.
    Zeng, X.
    Sun, T.
    Mo, Q.
    Dong, F.
    Wu, S.
    Zhu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1387 - S1387
  • [30] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
12345